Goldman Sachs Initiates Acorda Therapeutics With Neutral By: Benzinga via Benzinga December 05, 2014 at 08:57 AM EST Analysts at Goldman Sachs initiated coverage on shares of Acorda Therapeutics (NASDAQ: ACOR) with a Neutral rating. The target price ... Read More >> Related Stocks: Acorda Therapeutics